39
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      COVID-19 Vaccination Coverage Among Adolescents Aged 12–17 Years — United States, December 14, 2020–July 31, 2021

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Although severe COVID-19 illness and hospitalization are more common among adults, these outcomes can occur in adolescents ( 1 ). Nearly one third of adolescents aged 12–17 years hospitalized with COVID-19 during March 2020–April 2021 required intensive care, and 5% of those hospitalized required endotracheal intubation and mechanical ventilation ( 2 ). On December 11, 2020, the Food and Drug Administration (FDA) issued Emergency Use Authorization (EUA) of the Pfizer-BioNTech COVID-19 vaccine for adolescents aged 16–17 years; on May 10, 2021, the EUA was expanded to include adolescents aged 12–15 years; and on August 23, 2021, FDA granted approval of the vaccine for persons aged ≥16 years. To assess progress in adolescent COVID-19 vaccination in the United States, CDC assessed coverage with ≥1 dose* and completion of the 2-dose vaccination series † among adolescents aged 12–17 years using vaccine administration data for 49 U.S. states (all except Idaho) and the District of Columbia (DC) during December 14, 2020–July 31, 2021. As of July 31, 2021, COVID-19 vaccination coverage among U.S. adolescents aged 12–17 years was 42.4% for ≥1 dose and 31.9% for series completion. Vaccination coverage with ≥1 dose varied by state (range = 20.2% [Mississippi] to 70.1% [Vermont]) and for series completion (range = 10.7% [Mississippi] to 60.3% [Vermont]). By age group, 36.0%, 40.9%, and 50.6% of adolescents aged 12–13, 14–15, and 16–17 years, respectively, received ≥1 dose; 25.4%, 30.5%, and 40.3%, respectively, completed the vaccine series. Improving vaccination coverage and implementing COVID-19 prevention strategies are crucial to reduce COVID-19–associated morbidity and mortality among adolescents and to facilitate safer reopening of schools for in-person learning. Data on COVID-19 vaccine administration in the United States are reported to CDC by jurisdictions, pharmacies, and federal entities through immunization information systems (IISs), § the Vaccine Administration Management System (VAMS), ¶ or direct data submission.** Adolescents aged 12–17 years with valid residence in one of 49 states or DC who received ≥1 dose of a COVID-19 vaccine during December 14, 2020–July 31, 2021, and whose data were reported to CDC by August 11, 2021, were included in this analysis. †† COVID-19 vaccine doses administered to persons residing in Idaho were excluded because the state has data-sharing restrictions on information reported to CDC. Receipt of ≥1 COVID-19 vaccine dose and series completion among adolescents aged 12–17 years was calculated overall and stratified by age (12–13, 14–15, and 16–17 years), sex, and jurisdiction (49 states and DC). As of August 17, 2021, only the Pfizer-BioNTech vaccine had been authorized for use among adolescents aged 12–17 years in the United States. Moderna and Janssen (Johnson & Johnson) COVID-19 vaccines were not authorized under emergency use for this age group during the analysis period; however, for reasons that are not known, many adolescents were reported to have received these vaccines, and doses administered to adolescents were included in this analysis. Vaccination coverage by race and ethnicity was not calculated because of high rates of missing data. Population size by age group and sex was obtained from the U.S. Census Bureau’s 2019 Population Estimates Program ( 3 ). Second dose completion was calculated among adolescents who received ≥1 dose of a 2-dose COVID-19 vaccination series and for whom sufficient time to receive a second dose during the analysis period had elapsed. §§ Among adolescents who received the first dose of a 2-dose COVID-19 vaccination series, the proportions of adolescents who had already received the second dose, of those who had not received the second dose but were still within the recommended time interval to receive the second dose, and of those who had not received and were overdue for the second dose were calculated. Tests for statistical significance were not conducted because these data are reflective of the U.S. population (excluding Idaho) and were not based on population samples. All analyses were conducted using SAS software (version 9.4; SAS Institute). This activity was reviewed by CDC and was conducted consistent with applicable federal law and CDC policy. ¶¶ As of July 31, 2021, 42.4% of adolescents aged 12–17 years had received ≥1 dose of a COVID-19 vaccine (Table 1), and 31.9% had completed the vaccination series (Table 2). Adolescent COVID-19 vaccination coverage with ≥1 dose varied by state (range = 20.2% [Mississippi] to 70.1% [Vermont]), as it did for series completion (range = 10.7% [Mississippi] to 60.3% [Vermont]), with higher vaccination coverage in the Northeast and on the West Coast and lower vaccination coverage in the South (Figure). Coverage was higher among adolescents aged 16–17 years (50.6% for ≥1 dose; 40.3% for series completion) than among those aged 12–13 years (36.0% for ≥1 dose; 25.4% for series completion) and 14–15 years (40.9% for ≥1 dose; 30.5% for series completion). Vaccination coverage was similar among males and females across all age groups. TABLE 1 Receipt of ≥1 COVID-19 vaccine dose by adolescents aged 12–17 years,* by age group and sex † — United States, § December 14, 2020–July 31, 2021 Jurisdiction Age group and sex, no. (%) 12–17 yrs 12–13 yrs 14–15 yrs 16–17 yrs Total Female Male Total Female Male Total Female Male Total Female Male United States 10,677,934 (42.4) 5,425,265 (44.1) 5,216,450 (40.5) 3,094,245 (36.0) 1,543,152 (36.8) 1,541,710 (35.0) 3,454,771 (40.9) 1,750,329 (42.2) 1,693,216 (39.5) 4,128,918 (50.6) 2,131,784 (53.9) 1,981,524 (47.1) Alabama 77,773 (20.6) 40,050 (22.4) 37,692 (19.0) 127,065 (17.5) 11,189 (18.7) 11,094 (16.5) 25,257 (19.6) 12,996 (20.3) 12,256 (18.9) 30,221 (24.8) 15,865 (28.7) 14,342 (21.6) Alaska 23,706 (46.4) 11,621 (50.6) 11,788 (41.9) 14,859 (46.0) 3,279 (38.2) 3,480 (55.5) 7,627 (37.0) 3,755 (42.5) 3,789 (32.1) 9,241 (59.2) 4,587 (82.9) 4,519 (44.8) Arizona 224,638 (38.9) 114,136 (40.9) 109,744 (36.8) 201,971 (32.3) 32,501 (32.7) 32,543 (31.7) 72,338 (37.3) 36,750 (38.9) 35,297 (35.5) 87,023 (48.1) 44,885 (52.7) 41,904 (43.7) Arkansas 73,861 (30.3) 37,256 (31.6) 35,813 (28.6) 80,882 (25.0) 9,905 (24.7) 10,097 (24.8) 24,873 (31.2) 12,407 (30.4) 12,209 (31.5) 28,754 (34.7) 14,944 (40.3) 13,507 (29.5) California 1,642,427 (53.2) 836,970 (55.5) 801,906 (50.8) 1,054,889 (44.3) 233,673 (45.3) 232,862 (43.2) 541,389 (52.3) 275,356 (54.7) 264,914 (49.9) 633,560 (63.6) 327,941 (67.2) 304,130 (59.8) Colorado 222,780 (50.3) 113,015 (53.3) 109,520 (47.6) 147,908 (45.0) 33,118 (48.3) 33,343 (42.0) 73,879 (48.7) 37,316 (51.5) 36,481 (46.1) 82,383 (57.6) 42,581 (59.8) 39,696 (55.3) Connecticut 166,941 (62.3) 84,333 (64.6) 82,242 (59.9) 87,364 (55.1) 23,935 (55.1) 24,047 (54.7) 53,242 (58.7) 27,015 (62.4) 26,116 (55.1) 65,592 (72.9) 33,383 (76.0) 32,079 (69.7) Delaware 32,169 (45.2) 16,559 (49.0) 15,560 (41.6) 21,190 (44.0) 4,614 (50.5) 4,698 (39.0) 10,526 (37.8) 5,428 (34.9) 5,080 (41.2) 12,319 (55.7) 6,517 (71.3) 5,782 (44.6) District of Columbia 17,256 (52.3) 8,872 (53.3) 8,325 (50.9) 11,514 (49.8) 2,965 (56.6) 2,741 (43.7) 5,356 (46.0) 2,700 (38.3) 2,637 (57.5) 6,168 (62.6) 3,207 (73.4) 2,947 (53.7) Florida 558,957 (37.6) 286,050 (39.4) 272,548 (35.9) 514,351 (31.0) 80,517 (32.9) 78,894 (29.3) 183,765 (37.2) 93,750 (37.6) 89,911 (36.8) 215,683 (45.3) 111,783 (48.4) 103,743 (42.3) Georgia 271,600 (30.7) 138,608 (32.6) 132,222 (28.8) 307,972 (25.5) 39,194 (26.1) 39,086 (24.8) 87,107 (29.1) 44,308 (30.9) 42,597 (27.3) 105,965 (38.3) 55,106 (41.8) 50,539 (34.9) Hawaii 60,457 (63.7) 30,251 (67.7) 30,035 (59.8) 33,044 (52.3) 8,501 (54.1) 8,725 (50.4) 19,774 (64.0) 9,869 (74.0) 9,857 (56.0) 23,409 (75.7) 11,881 (76.0) 11,453 (74.8) Illinois 527,953 (53.2) 268,107 (54.1) 257,707 (52.0) 331,413 (45.4) 75,084 (44.8) 74,889 (45.7) 175,184 (52.1) 88,684 (52.1) 85,790 (51.7) 202,272 (62.4) 104,339 (65.9) 97,028 (58.5) Indiana 164,717 (29.8) 84,039 (31.5) 79,638 (28.0) 194,055 (24.6) 23,834 (25.1) 23,786 (24.0) 52,778 (29.8) 26,775 (31.6) 25,704 (27.9) 64,144 (35.4) 33,430 (38.2) 30,148 (32.2) Iowa 88,317 (36.7) 45,436 (38.6) 42,643 (34.8) 83,053 (31.8) 13,341 (32.8) 13,058 (30.8) 28,451 (36.9) 14,440 (36.2) 13,970 (37.5) 33,421 (41.6) 17,655 (47.3) 15,615 (36.4) Kansas 88,601 (36.4) 45,509 (38.0) 42,995 (34.9) 84,150 (31.6) 13,211 (30.7) 13,352 (32.5) 27,907 (34.8) 14,328 (40.8) 13,557 (30.1) 34,100 (43.3) 17,970 (43.1) 16,086 (43.3) Kentucky 115,204 (32.7) 59,363 (34.5) 55,723 (31.0) 122,071 (27.8) 17,009 (27.7) 16,927 (27.9) 37,571 (33.0) 19,163 (35.5) 18,375 (30.6) 43,680 (37.6) 23,191 (40.7) 20,421 (34.4) Louisiana 81,272 (21.9) 41,478 (23.4) 39,560 (20.3) 131,531 (17.7) 11,736 (19.3) 11,536 (16.3) 26,369 (21.6) 13,273 (22.2) 13,019 (20.9) 31,616 (26.7) 16,469 (29.1) 15,005 (24.4) Maine 48,729 (55.1) 24,474 (59.0) 23,874 (50.9) 27,699 (53.3) 7,247 (64.3) 7,370 (44.9) 16,031 (52.4) 8,004 (54.5) 7,858 (49.4) 17,937 (59.6) 9,223 (59.6) 8,646 (59.2) Maryland 263,433 (56.3) 132,880 (57.8) 130,206 (54.7) 163,386 (49.1) 39,948 (51.2) 40,174 (47.1) 84,806 (53.6) 42,484 (52.7) 42,206 (54.4) 98,420 (67.4) 50,448 (70.9) 47,826 (63.8) Massachusetts 319,741 (65.7) 161,726 (68.5) 157,494 (62.9) 158,110 (59.9) 47,185 (62.7) 47,336 (57.1) 105,067 (65.2) 53,176 (64.4) 51,711 (65.7) 120,042 (71.7) 61,365 (78.3) 58,447 (65.7) Michigan 273,071 (36.0) 139,194 (38.1) 133,776 (34.1) 254,314 (30.6) 39,045 (31.8) 38,746 (29.5) 86,078 (34.7) 43,910 (36.8) 42,132 (32.7) 109,164 (42.7) 56,239 (45.5) 52,898 (40.0) Minnesota 198,287 (44.3) 101,571 (45.8) 95,698 (42.4) 149,301 (40.8) 30,696 (39.3) 30,025 (42.1) 60,068 (38.7) 30,610 (40.9) 29,257 (36.4) 77,289 (54.1) 40,265 (58.4) 36,416 (49.3) Mississippi 49,940 (20.2) 25,444 (21.0) 24,454 (19.3) 86,695 (16.7) 7,162 (17.7) 7,272 (15.7) 16,559 (21.4) 8,298 (20.3) 8,245 (22.7) 18,931 (22.6) 9,984 (25.0) 8,937 (20.4) Missouri 152,486 (32.4) 77,515 (33.0) 74,807 (31.7) 158,781 (28.9) 22,844 (29.3) 23,025 (28.5) 49,384 (31.0) 25,006 (31.7) 24,325 (30.2) 57,185 (37.5) 29,665 (38.0) 27,457 (37.0) Montana 23,962 (30.3) 12,105 (31.5) 11,683 (28.8) 25,348 (28.9) 3,579 (28.1) 3,669 (29.1) 7,428 (28.9) 3,730 (28.5) 3,638 (28.9) 9,209 (32.9) 4,796 (38.0) 4,376 (28.5) Nebraska 62,131 (39.2) 31,723 (39.8) 30,292 (38.5) 56,881 (33.1) 9,447 (31.5) 9,343 (34.7) 19,599 (37.1) 9,928 (40.0) 9,649 (34.5) 23,719 (48.7) 12,348 (49.6) 11,300 (47.5) Nevada 89,835 (37.2) 46,021 (37.7) 43,775 (36.6) 85,434 (29.8) 12,717 (30.8) 12,723 (28.8) 29,148 (36.3) 14,933 (34.9) 14,202 (37.8) 35,241 (46.5) 18,371 (48.4) 16,850 (44.6) New Hampshire 48,188 (49.5) 24,264 (49.9) 23,250 (47.7) 34,943 (38.1) 6,575 (38.3) 6,609 (37.2) 15,129 (51.1) 7,567 (47.1) 7,332 (54.2) 19,747 (60.1) 10,122 (65.7) 9,309 (53.3) New Jersey 357,267 (52.5) 180,504 (54.7) 175,521 (50.0) 232,003 (43.8) 50,304 (42.3) 51,137 (45.2) 113,832 (50.9) 57,509 (54.3) 55,960 (47.5) 141,702 (62.9) 72,691 (69.2) 68,424 (56.9) New Mexico 92,891 (55.1) 46,824 (55.5) 44,864 (53.1) 57,115 (49.5) 13,992 (49.8) 13,800 (47.6) 29,505 (50.9) 14,745 (49.8) 14,367 (50.7) 35,137 (65.5) 18,087 (68.0) 16,697 (61.6) New York 651,562 (46.6) 328,743 (48.5) 319,985 (44.5) 471,237 (39.3) 91,375 (39.4) 93,069 (38.9) 205,664 (44.3) 103,529 (46.5) 101,489 (42.0) 260,904 (56.6) 133,839 (60.1) 125,427 (52.6) North Carolina 288,722 (35.4) 147,723 (35.7) 139,514 (34.8) 280,592 (29.4) 41,310 (28.5) 40,939 (30.1) 95,543 (35.3) 48,666 (35.0) 46,473 (35.3) 110,577 (42.0) 57,747 (44.3) 52,102 (39.1) North Dakota 13,910 (26.3) 7,084 (25.4) 6,613 (26.5) 18,993 (20.2) 1,888 (20.4) 1,894 (19.5) 4,533 (27.4) 2,290 (24.1) 2,175 (30.8) 5,535 (32.0) 2,906 (31.8) 2,544 (31.3) Ohio 284,374 (31.9) 145,410 (33.8) 138,167 (29.9) 300,214 (27.1) 40,975 (28.2) 40,302 (26.0) 89,895 (29.9) 45,960 (31.6) 43,719 (28.2) 113,035 (38.8) 58,475 (42.1) 54,146 (35.5) Oklahoma 92,409 (29.1) 47,313 (31.4) 44,973 (27.1) 113,915 (23.4) 13,242 (25.7) 13,346 (21.4) 29,283 (29.1) 15,020 (30.0) 14,228 (28.2) 36,505 (35.5) 19,051 (38.7) 17,399 (32.5) Oregon 147,476 (49.3) 74,896 (49.7) 72,231 (48.8) 100,819 (43.5) 21,971 (44.0) 21,828 (42.9) 48,739 (48.1) 24,714 (47.6) 23,927 (48.3) 54,859 (56.8) 28,211 (57.6) 26,476 (55.5) Pennsylvania 437,303 (47.7) 219,211 (48.7) 209,686 (44.8) 308,332 (41.3) 62,448 (41.8) 62,623 (39.4) 140,842 (45.2) 70,283 (46.6) 67,547 (42.1) 168,972 (56.7) 86,480 (57.7) 79,516 (53.7) Rhode Island 42,660 (55.4) 21,683 (60.8) 20,919 (50.6) 25,863 (48.2) 6,167 (45.7) 6,290 (50.9) 13,645 (51.2) 7,024 (61.9) 6,595 (43.1) 16,544 (67.4) 8,492 (78.4) 8,034 (58.6) South Carolina 100,830 (25.8) 51,820 (26.7) 48,946 (24.9) 135,830 (19.9) 13,591 (20.5) 13,384 (19.2) 33,001 (24.6) 17,005 (25.3) 15,977 (23.9) 40,842 (33.7) 21,224 (34.9) 19,585 (32.5) South Dakota 24,848 (34.4) 12,468 (34.6) 11,989 (33.1) 24,483 (30.1) 3,612 (32.6) 3,661 (27.3) 8,051 (30.9) 4,073 (29.1) 3,850 (31.9) 9,439 (43.5) 4,783 (43.5) 4,478 (41.8) Tennessee 126,159 (24.3) 65,267 (26.1) 60,591 (22.6) 185,246 (19.6) 18,164 (20.1) 18,156 (19.2) 40,295 (24.0) 20,848 (24.2) 19,407 (23.8) 49,495 (29.9) 26,255 (35.8) 23,028 (24.9) Texas 1,028,789 (40.6) 521,461 (42.2) 506,643 (39.0) 854,580 (34.6) 147,957 (35.6) 147,505 (33.6) 330,444 (38.5) 167,302 (39.9) 162,971 (37.1) 402,745 (49.1) 206,202 (51.6) 196,167 (46.6) Utah 129,559 (41.9) 65,495 (43.8) 63,818 (40.0) 106,783 (34.6) 18,393 (34.5) 18,549 (34.7) 39,977 (38.8) 20,029 (41.4) 19,925 (36.5) 52,615 (53.1) 27,073 (56.6) 25,344 (49.3) Vermont 28,904 (70.1) 14,332 (74.4) 14,474 (65.9) 11,732 (75.0) 4,306 (83.5) 4,464 (67.9) 9,454 (70.3) 4,790 (91.7) 4,627 (56.3) 10,649 (66.3) 5,236 (58.9) 5,383 (75.1) Virginia 342,958 (53.7) 173,904 (56.1) 168,793 (51.3) 222,929 (45.3) 50,509 (46.5) 50,461 (44.1) 113,259 (53.0) 57,040 (54.8) 56,153 (51.2) 128,655 (63.6) 66,355 (68.2) 62,179 (59.2) Washington 296,782 (53.1) 149,501 (53.6) 145,592 (52.0) 192,800 (48.7) 46,631 (49.0) 46,691 (47.8) 95,740 (50.0) 47,895 (48.3) 47,255 (51.2) 107,187 (61.3) 54,975 (64.9) 51,646 (57.3) West Virginia 38,159 (30.2) 19,127 (31.5) 18,459 (28.2) 44,298 (23.8) 5,126 (24.7) 5,263 (22.3) 12,061 (30.2) 6,090 (32.4) 5,782 (27.3) 15,564 (37.1) 7,911 (37.2) 7,414 (35.8) Wisconsin 174,211 (39.9) 88,947 (41.5) 84,996 (38.2) 142,836 (35.8) 25,720 (38.3) 25,427 (33.6) 55,260 (36.8) 28,010 (37.0) 27,178 (36.4) 67,750 (47.1) 35,217 (49.2) 32,391 (44.9) Wyoming 9,729 (20.4) 4,982 (21.7) 4,706 (19.0) 18,337 (15.8) 1,420 (16.5) 1,471 (15.2) 3,058 (20.9) 1,548 (19.9) 1,497 (21.8) 3,772 (25.7) 2,014 (30.8) 1,738 (21.4) * Receipt of ≥1 COVID-19 vaccine dose is defined either as receiving at least one of the 2 doses of the Pfizer-BioNTech or Moderna vaccines or a single dose of the Janssen (Johnson & Johnson) vaccine. As of August 17, 2021, only the Pfizer-BioNTech vaccine had been authorized for use among adolescents aged 12–17 years. Moderna and Janssen COVID-19 vaccines were not authorized under emergency use for this age group during the analysis period; however, these vaccinations were included in this analysis. † Fewer than 0.5% of the records were missing information on sex. § COVID-19 vaccine doses administered to adolescents residing in Idaho were excluded because the state has data-sharing restrictions on information reported to CDC. TABLE 2 COVID-19 vaccination coverage among adolescents aged 12–17 years who completed the vaccine series,* by age group and sex † — United States, § December 14, 2020–July 31, 2021 Jurisdiction Age group and sex, no. (%) 12–17 yrs 12–13 yrs 14–15 yrs 16–17 yrs Total Female Male Total Female Male Total Female Male Total Female Male United States 8,045,685 (31.9) 4,117,404 (33.5) 3,905,344 (30.3) 2,183,597 (25.4) 1,093,057 (26.0) 1,085,039 (24.7) 2,570,498 (30.5) 1,311,724 (31.6) 1,251,765 (29.2) 3,291,590 (40.3) 1,712,623 (43.3) 1,568,540 (37.3) Alabama 40,925 (10.8) 21,303 (11.9) 19,606 (9.9) 10,360 (8.2) 5,234 (8.7) 5,118 (7.6) 12,421 (9.6) 6,452 (10.1) 5,969 (9.2) 18,144 (14.9) 9,617 (17.4) 8,519 (12.8) Alaska 18,394 (36.0) 9,066 (39.5) 9,148 (32.5) 4,947 (33.3) 2,384 (27.7) 2,522 (40.2) 5,678 (27.5) 2,778 (31.4) 2,847 (24.1) 7,769 (49.7) 3,904 (70.6) 3,779 (37.4) Arizona 167,297 (29.0) 85,471 (30.6) 81,203 (27.3) 44,661 (22.1) 22,273 (22.4) 22,209 (21.7) 52,639 (27.1) 26,854 (28.4) 25,546 (25.7) 69,997 (38.7) 36,344 (42.6) 33,448 (34.9) Arkansas 41,891 (17.2) 21,742 (18.4) 19,956 (15.9) 10,494 (13.0) 5,259 (13.1) 5,194 (12.7) 13,552 (17.0) 6,945 (17.0) 6,551 (16.9) 17,845 (21.5) 9,538 (25.7) 8,211 (17.9) California 1,271,593 (41.2) 652,802 (43.3) 616,318 (39.0) 344,509 (32.7) 172,803 (33.5) 171,083 (31.7) 416,508 (40.3) 213,322 (42.4) 202,396 (38.1) 510,576 (51.2) 266,677 (54.6) 242,839 (47.7) Colorado 185,447 (41.9) 94,420 (44.5) 90,901 (39.5) 52,056 (35.2) 25,885 (37.8) 26,150 (32.9) 61,301 (40.4) 31,074 (42.9) 30,191 (38.2) 72,090 (50.4) 37,461 (52.6) 34,560 (48.1) Connecticut 136,730 (51.0) 69,481 (53.2) 66,983 (48.8) 36,973 (42.3) 18,513 (42.6) 18,368 (41.8) 43,625 (48.1) 22,287 (51.5) 21,253 (44.8) 56,132 (62.4) 28,681 (65.3) 27,362 (59.5) Delaware 25,675 (36.1) 13,313 (39.4) 12,334 (33.0) 7,027 (33.2) 3,496 (38.2) 3,524 (29.3) 8,378 (30.1) 4,378 (28.2) 3,990 (32.3) 10,270 (46.4) 5,439 (59.5) 4,820 (37.2) District of Columbia 11,239 (34.1) 5,818 (34.9) 5,393 (33.0) 3,574 (31.0) 1,847 (35.2) 1,716 (27.4) 3,607 (31.0) 1,849 (26.2) 1,748 (38.1) 4,058 (41.2) 2,122 (48.6) 1,929 (35.1) Florida 377,443 (25.4) 194,735 (26.8) 182,570 (24.0) 98,344 (19.1) 49,892 (20.4) 48,418 (18.0) 120,847 (24.5) 62,121 (24.9) 58,694 (24.0) 158,252 (33.2) 82,722 (35.8) 75,458 (30.7) Georgia 166,329 (18.8) 85,830 (20.2) 80,219 (17.5) 41,215 (13.4) 20,691 (13.8) 20,437 (13.0) 48,426 (16.2) 24,922 (17.4) 23,455 (15.0) 76,688 (27.7) 40,217 (30.5) 36,327 (25.1) Hawaii 35,203 (37.1) 17,549 (39.3) 17,546 (34.9) 9,931 (30.1) 4,831 (30.7) 5,072 (29.3) 11,450 (37.0) 5,705 (42.8) 5,715 (32.5) 13,822 (44.7) 7,013 (44.9) 6,759 (44.2) Illinois 348,478 (35.1) 179,085 (36.1) 168,328 (33.9) 95,818 (28.9) 48,301 (28.8) 47,255 (28.8) 113,863 (33.9) 58,356 (34.3) 55,143 (33.2) 138,797 (42.8) 72,428 (45.8) 65,930 (39.7) Indiana 131,406 (23.8) 67,329 (25.2) 63,257 (22.2) 35,025 (18.0) 17,450 (18.4) 17,450 (17.6) 41,394 (23.4) 21,124 (24.9) 20,030 (21.7) 54,987 (30.4) 28,755 (32.8) 25,777 (27.6) Iowa 70,809 (29.4) 36,654 (31.1) 34,002 (27.7) 19,670 (23.7) 9,953 (24.5) 9,692 (22.8) 22,623 (29.3) 11,540 (28.9) 11,059 (29.7) 28,516 (35.5) 15,161 (40.6) 13,251 (30.9) Kansas 61,300 (25.2) 31,698 (26.4) 29,559 (24.0) 16,594 (19.7) 8,240 (19.2) 8,339 (20.3) 18,868 (23.5) 9,778 (27.8) 9,082 (20.2) 25,838 (32.8) 13,680 (32.8) 12,138 (32.7) Kentucky 81,664 (23.2) 42,709 (24.8) 38,895 (21.6) 22,107 (18.1) 11,199 (18.2) 10,903 (18.0) 26,034 (22.8) 13,521 (25.1) 12,500 (20.8) 33,523 (28.8) 17,989 (31.6) 15,492 (26.1) Louisiana 46,411 (12.5) 24,126 (13.6) 22,181 (11.4) 11,607 (8.8) 5,905 (9.7) 5,695 (8.0) 13,932 (11.4) 7,128 (11.9) 6,772 (10.9) 20,872 (17.6) 11,093 (19.6) 9,714 (15.8) Maine 42,857 (48.5) 21,496 (51.9) 21,044 (44.8) 12,259 (44.3) 5,993 (53.1) 6,149 (37.4) 14,157 (46.2) 7,069 (48.1) 6,953 (43.7) 16,441 (54.7) 8,434 (54.5) 7,942 (54.4) Maryland 218,233 (46.7) 110,698 (48.2) 107,376 (45.1) 62,420 (38.2) 31,169 (39.9) 31,214 (36.6) 70,372 (44.5) 35,469 (44.0) 34,851 (44.9) 85,441 (58.5) 44,060 (61.9) 41,311 (55.1) Massachusetts 263,919 (54.2) 134,332 (56.9) 129,099 (51.5) 74,471 (47.1) 37,267 (49.5) 37,081 (44.7) 86,063 (53.4) 43,839 (53.1) 42,066 (53.5) 103,385 (61.8) 53,226 (67.9) 49,952 (56.2) Michigan 229,551 (30.3) 117,541 (32.1) 111,939 (28.5) 61,506 (24.2) 30,932 (25.2) 30,548 (23.3) 72,163 (29.1) 36,968 (31.0) 35,175 (27.3) 95,882 (37.5) 49,641 (40.2) 46,216 (34.9) Minnesota 174,700 (39.0) 89,821 (40.5) 84,347 (37.4) 50,776 (34.0) 25,668 (32.9) 25,006 (35.1) 56,104 (36.1) 28,844 (38.5) 27,156 (33.8) 67,820 (47.4) 35,309 (51.2) 32,185 (43.5) Mississippi 26,576 (10.7) 13,709 (11.3) 12,846 (10.2) 6,393 (7.4) 3,182 (7.9) 3,204 (6.9) 8,134 (10.5) 4,094 (10.0) 4,033 (11.1) 12,049 (14.4) 6,433 (16.1) 5,609 (12.8) Missouri 104,029 (22.1) 53,410 (22.7) 50,568 (21.4) 28,825 (18.2) 14,385 (18.5) 14,432 (17.8) 32,843 (20.6) 16,854 (21.4) 15,979 (19.8) 42,361 (27.8) 22,171 (28.4) 20,157 (27.1) Montana 18,046 (22.8) 9,197 (23.9) 8,794 (21.7) 5,167 (20.4) 2,551 (20.0) 2,598 (20.6) 5,430 (21.2) 2,784 (21.3) 2,626 (20.9) 7,449 (26.6) 3,862 (30.6) 3,570 (23.2) Nebraska 48,472 (30.6) 25,035 (31.4) 23,394 (29.8) 13,509 (23.7) 6,854 (22.9) 6,647 (24.7) 15,152 (28.7) 7,759 (31.3) 7,384 (26.4) 19,811 (40.7) 10,422 (41.9) 9,363 (39.4) Nevada 55,558 (23.0) 28,686 (23.5) 26,854 (22.5) 14,043 (16.4) 7,011 (17.0) 7,030 (15.9) 17,412 (21.7) 8,995 (21.0) 8,411 (22.4) 24,103 (31.8) 12,680 (33.4) 11,413 (30.2) New Hampshire 39,480 (40.5) 19,952 (41.0) 18,996 (38.9) 10,267 (29.4) 5,083 (29.6) 5,094 (28.7) 12,290 (41.5) 6,173 (38.4) 5,945 (43.9) 16,923 (51.5) 8,696 (56.4) 7,957 (45.5) New Jersey 289,682 (42.5) 146,961 (44.6) 141,715 (40.3) 77,253 (33.3) 38,290 (32.2) 38,734 (34.3) 92,001 (41.1) 46,666 (44.1) 45,052 (38.2) 120,428 (53.4) 62,005 (59.0) 57,929 (48.2) New Mexico 72,669 (43.1) 37,085 (44.0) 35,178 (41.7) 20,417 (35.7) 10,265 (36.5) 10,012 (34.5) 22,917 (39.6) 11,613 (39.2) 11,184 (39.5) 29,335 (54.6) 15,207 (57.2) 13,982 (51.6) New York 537,956 (38.5) 272,326 (40.2) 263,665 (36.6) 143,966 (30.6) 71,259 (30.7) 72,385 (30.2) 169,430 (36.5) 85,566 (38.4) 83,440 (34.5) 224,560 (48.7) 115,501 (51.9) 107,840 (45.2) North Carolina 210,162 (25.8) 108,311 (26.2) 100,839 (25.2) 55,824 (19.9) 28,001 (19.3) 27,612 (20.3) 68,736 (25.4) 35,229 (25.3) 33,228 (25.2) 85,602 (32.5) 45,081 (34.6) 39,999 (30.0) North Dakota 10,254 (19.4) 5,257 (18.9) 4,842 (19.4) 2,516 (13.2) 1,259 (13.6) 1,219 (12.5) 3,234 (19.5) 1,628 (17.2) 1,556 (22.1) 4,504 (26.1) 2,370 (26.0) 2,067 (25.4) Ohio 239,023 (26.8) 122,890 (28.6) 115,636 (25.0) 63,374 (21.1) 32,046 (22.0) 31,238 (20.2) 74,684 (24.8) 38,484 (26.4) 36,083 (23.3) 100,965 (34.7) 52,360 (37.7) 48,315 (31.7) Oklahoma 61,250 (19.3) 31,546 (20.9) 29,633 (17.8) 15,691 (13.8) 7,764 (15.0) 7,913 (12.7) 18,709 (18.6) 9,633 (19.2) 9,056 (18.0) 26,850 (26.1) 14,149 (28.8) 12,664 (23.7) Oregon 126,346 (42.3) 64,593 (42.8) 61,618 (41.6) 36,145 (35.9) 18,188 (36.4) 17,937 (35.3) 41,459 (40.9) 21,114 (40.7) 20,319 (41.0) 48,742 (50.4) 25,291 (51.7) 23,362 (49.0) Pennsylvania 303,836 (33.1) 153,011 (34.0) 145,168 (31.0) 84,516 (27.4) 41,529 (27.8) 41,414 (26.0) 98,297 (31.6) 49,226 (32.6) 47,005 (29.3) 121,023 (40.6) 62,256 (41.5) 56,749 (38.3) Rhode Island 35,520 (46.1) 18,100 (50.7) 17,380 (42.0) 9,733 (37.6) 4,786 (35.4) 4,938 (40.0) 11,386 (42.7) 5,862 (51.6) 5,508 (36.0) 14,401 (58.7) 7,452 (68.8) 6,934 (50.6) South Carolina 72,130 (18.4) 37,476 (19.3) 34,621 (17.6) 17,802 (13.1) 8,967 (13.5) 8,831 (12.7) 22,947 (17.1) 11,939 (17.7) 10,996 (16.4) 31,381 (25.9) 16,570 (27.3) 14,794 (24.5) South Dakota 16,383 (22.7) 8,318 (23.1) 7,813 (21.6) 4,264 (17.4) 2,113 (19.1) 2,108 (15.7) 5,037 (19.3) 2,585 (18.5) 2,374 (19.7) 7,082 (32.6) 3,620 (32.9) 3,331 (31.1) Tennessee 87,019 (16.8) 45,491 (18.2) 41,307 (15.4) 22,260 (12.0) 11,200 (12.4) 11,035 (11.6) 26,342 (15.7) 13,724 (15.9) 12,597 (15.4) 38,417 (23.2) 20,567 (28.0) 17,675 (19.1) Texas 718,918 (28.4) 369,600 (29.9) 348,945 (26.9) 193,523 (22.6) 97,354 (23.4) 96,096 (21.9) 225,520 (26.2) 115,724 (27.6) 109,695 (24.9) 299,875 (36.5) 156,522 (39.1) 143,154 (34.0) Utah 96,759 (31.3) 49,212 (32.9) 47,466 (29.8) 25,119 (23.5) 12,578 (23.6) 12,530 (23.4) 29,095 (28.3) 14,641 (30.3) 14,449 (26.4) 42,545 (42.9) 21,993 (46.0) 20,487 (39.9) Vermont 24,881 (60.3) 12,395 (64.3) 12,437 (56.6) 7,388 (63.0) 3,657 (70.9) 3,720 (56.6) 8,118 (60.4) 4,095 (78.4) 4,006 (48.8) 9,375 (58.4) 4,643 (52.2) 4,711 (65.7) Virginia 283,385 (44.3) 144,360 (46.6) 138,878 (42.2) 79,268 (35.6) 39,685 (36.5) 39,546 (34.6) 93,389 (43.7) 47,282 (45.5) 46,077 (42.0) 110,728 (54.7) 57,393 (59.0) 53,255 (50.7) Washington 245,243 (43.9) 124,122 (44.5) 119,901 (42.8) 73,427 (38.1) 36,514 (38.4) 36,573 (37.4) 79,630 (41.6) 40,075 (40.4) 39,149 (42.5) 92,186 (52.7) 47,533 (56.1) 44,179 (49.0) West Virginia 27,203 (21.6) 13,567 (22.3) 13,174 (20.1) 6,953 (15.7) 3,372 (16.3) 3,453 (14.6) 8,505 (21.3) 4,299 (22.9) 4,066 (19.2) 11,745 (28.0) 5,896 (27.7) 5,655 (27.3) Wisconsin 140,545 (32.2) 72,235 (33.7) 68,167 (30.6) 37,736 (26.4) 19,067 (28.4) 18,641 (24.6) 43,634 (29.0) 22,269 (29.4) 21,335 (28.6) 59,175 (41.2) 30,899 (43.1) 28,191 (39.1) Wyoming 6,866 (14.4) 3,540 (15.4) 3,305 (13.4) 1,874 (10.2) 912 (10.6) 956 (9.8) 2,162 (14.8) 1,088 (14.0) 1,070 (15.6) 2,830 (19.3) 1,540 (23.6) 1,279 (15.7) * Vaccine series completion was defined as receiving either both doses of the Pfizer-BioNTech or Moderna vaccines, including mismatched products between the first and second dose (i.e., Pfizer-BioNTech for the first dose and Moderna for the second dose or vice versa) or a single dose for the Janssen (Johnson & Johnson) vaccine. As of August 17, 2021, only the Pfizer-BioNTech vaccine had been authorized for use among adolescents aged 12–17 years. Moderna and Janssen COVID-19 vaccines were not authorized under emergency use for this age group during the analysis period; however, these vaccinations were included in this analysis. † Fewer than 0.5% of the records were missing information on sex. § COVID-19 vaccine doses administered to adolescents residing in Idaho were excluded because the state has data-sharing restrictions on information reported to CDC. FIGURE Percentage of adolescents aged 12–17 years who completed the COVID-19 vaccination series* ,†— United States, § December 14, 2020–July 31, 2021 Abbreviation: DC = District of Columbia. * As of August 17, 2021, only the Pfizer-BioNTech vaccine had been authorized for use among adolescents aged 12–17 years. Moderna and Janssen (Johnson & Johnson) COVID-19 vaccines were not authorized under emergency use for this age group during the analysis period; however, many adolescents had documentation of receipt of these vaccines. Thus, these vaccine doses were included in this analysis if they were administered to adolescents aged 12–17 years. † Series completion was defined as receipt of either both doses of the Pfizer-BioNTech or Moderna vaccines, including those who might have received mismatched products between the first and second dose (i.e., Pfizer-BioNTech for the first dose and Moderna for the second dose or vice versa) or a single dose of the Janssen vaccine. § COVID-19 vaccine doses administered to adolescents residing in Idaho were excluded because the state has data-sharing restrictions on information reported to CDC. The figure is a map of the United States showing the percentage of adolescents aged 12–17 years who completed the COVID-19 vaccination series during December 14, 2020–July 31, 2021. Overall, 86.8% of adolescents aged 12–17 years who received the first dose of a 2-dose COVID-19 vaccination series*** received the second dose within the recommended interval. A total of 2.4% had not received the second dose but were within the allowable interval, and 10.8% were overdue for the second dose (i.e., >42 days since receipt of the first dose) (Supplementary Table, https://stacks.cdc.gov/view/cdc/109000). Discussion Among all U.S. adolescents aged 12–17 years who received the first dose of a 2-dose COVID-19 vaccine series, the vast majority received the second dose, indicating high adherence to completing the COVID-19 vaccine series. However, as of July 31, 2021, only 42.4% of adolescents had received ≥1 dose of a COVID-19 vaccine, and fewer than one third (31.9%) had completed the vaccination series. Further, vaccination coverage varied widely by state, with those in the Northeast and on the West Coast reporting the highest COVID-19 vaccination coverage among adolescents. Vaccination coverage also varied widely by age group, with reported coverage higher among those aged 16–17 years compared with those aged 12–15 years. This is likely because the older age group has been vaccine-eligible for a longer period (i.e., since December 2020). After the start of the COVID-19 pandemic, many schools shifted to virtual or hybrid learning. Because in-person learning fosters social and emotional development, ††† safely returning to schools for in-person learning remains a goal. However, given the rapid emergence and spread of the highly transmissible B.1.617.2 (Delta) variant of SARS-CoV-2, the virus that causes COVID-19, and the increase in cases and hospitalizations among children and adolescents ( 1 ), ensuring high adolescent vaccination coverage is crucial to a safer return to the classroom. Unvaccinated or undervaccinated adolescents can become ill with COVID-19 and spread the SARS-CoV-2 virus in schools, and by extension, in local communities, placing other populations at risk. School systems can consider implementing layered prevention strategies consistent with CDC’s guidance for COVID-19 prevention in schools, including universal indoor masking regardless of vaccination status, improving ventilation, screening testing, physical distancing where feasible, and contact tracing in combination with quarantine and isolation. As the 2021–22 school year begins, concerted public health efforts are needed to increase COVID-19 vaccination coverage among adolescents in addition to implementing COVID-19 prevention strategies based on community transmission. Public health practitioners can use various measures to increase adolescent COVID-19 vaccination coverage. Building on lessons from the public-private partnership between CDC and retail pharmacies in the Federal Retail Pharmacy Partnership §§§ regarding vaccination clinics offered for selected population groups at different times throughout the response ( 4 ), local public health agencies and pharmacies could partner with school districts and school systems to provide COVID-19 vaccinations to students at schools. Vaccine administration on site at schools is an effective, evidence-based intervention that improves childhood and adolescent vaccination rates for routinely recommended vaccines ( 5 ). State and local governments, school administrators, community leaders, health care professionals, and public health practitioners can facilitate safer return to schools and improve equity among sociodemographic groups by prioritizing COVID-19 vaccination among adolescents and incorporating on-site school vaccinations for eligible students ( 6 , 7 ). In addition, on-site vaccination clinics might also be planned in coordination with other school-based vaccination programs, such as those for seasonal influenza and routine adolescent vaccination. Concerted outreach can help inform adolescents and their parents about the importance of COVID-19 vaccination. Effective outreach with tailored communication could help improve vaccine confidence, acceptance, and coverage among adolescents and their parents. In a recent report, only 56% of parents of unvaccinated adolescents aged 12–17 years expressed intent for their adolescent to receive a COVID-19 vaccine ( 8 ). Given that parental vaccination status is a marker for adolescent vaccination status, ¶¶¶ vaccine hesitancy or antivaccination sentiments among parents might directly lead to missed opportunities to vaccinate adolescents ( 9 ). Among adolescents and their parents who were surveyed about their intent to receive a COVID-19 vaccine, many reported that having more information about the safety and efficacy of COVID-19 vaccines would increase their likelihood of receiving a vaccine ( 8 ). Public health practitioners can use multimodal outreach efforts involving a variety of traditional and social media platforms to engage adolescents and their parents to improve vaccination acceptance and coverage. Further, state and local governments can consider strategies that encourage receipt by adolescents of all vaccines recommended by the Advisory Committee on Immunization Practices, especially given the declines in routine childhood and adolescent vaccinations during the pandemic ( 10 ). The findings in this report are subject to at least five limitations. First, vaccination coverage rates were aggregated and analyzed only at the state level. Calculating coverage at more specific levels (e.g., by county or urban-rural classification) could potentially identify geographic areas with low vaccination coverage rates. Second, because Idaho was excluded from the analysis, the findings are not representative of the entire United States. Third, adolescents who received COVID-19 vaccines from different entities that used different methods for submitting data (e.g., if the first dose was administered at a pharmacy and the second dose was given at a mass vaccination site) might not have their first and second doses linked, which could have led to underestimation of the percentage of adolescents who completed the vaccination series. Fourth, if an adolescent had inadvertently received a different recipient ID when receiving their second dose, first and second doses could not be linked. Finally, vaccination coverage could not be calculated on the basis of race and ethnicity because of incomplete reporting. An estimated 2 million COVID-19 cases and approximately 300 associated deaths have been reported among children aged 5–17 years since the start of the COVID-19 pandemic ( 1 ). As persons in younger age groups become eligible for COVID-19 vaccination, public health practitioners, health care professionals, school administrators, and state and local governments can use evidence-based practices to decrease barriers to vaccination and increase confidence in COVID-19 vaccines, which can help facilitate the safer return to in-person learning at schools and ultimately reduce COVID-19–associated morbidity and mortality. Summary What is already known about this topic? Although more common among adults, severe COVID-19 illness and hospitalization occur among adolescents. What is added by this report? As of July 31, 2021, coverage with ≥1 dose of COVID-19 vaccine among adolescents aged 12–17 years was 42%, and 32% had completed the series. Series completion rates varied widely by state, ranging from 11% to 60%, and was 25% for adolescents aged 12–13 years, 30% for those aged 14–15 years, and 40% for those aged 16–17 years. What are the implications for public health practice? Improving adolescent COVID-19 vaccination coverage is crucial to reduce COVID-19–associated morbidity and mortality among adolescents and can help facilitate safer reopening of schools for in-person learning.

          Related collections

          Most cited references6

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Impact of the COVID-19 Pandemic on Administration of Selected Routine Childhood and Adolescent Vaccinations — 10 U.S. Jurisdictions, March–September 2020

            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Hospitalization of Adolescents Aged 12–17 Years with Laboratory-Confirmed COVID-19 — COVID-NET, 14 States, March 1, 2020–April 24, 2021

              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Early COVID-19 First-Dose Vaccination Coverage Among Residents and Staff Members of Skilled Nursing Facilities Participating in the Pharmacy Partnership for Long-Term Care Program — United States, December 2020–January 2021

              Residents and staff members of long-term care facilities (LTCFs), because they live and work in congregate settings, are at increased risk for infection with SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19) ( 1 , 2 ). In particular, skilled nursing facilities (SNFs), LTCFs that provide skilled nursing care and rehabilitation services for persons with complex medical needs, have been documented settings of COVID-19 outbreaks ( 3 ). In addition, residents of LTCFs might be at increased risk for severe outcomes because of their advanced age or the presence of underlying chronic medical conditions ( 4 ). As a result, the Advisory Committee on Immunization Practices has recommended that residents and staff members of LTCFs be offered vaccination in the initial COVID-19 vaccine allocation phase (Phase 1a) in the United States ( 5 ). In December 2020, CDC launched the Pharmacy Partnership for Long-Term Care Program* to facilitate on-site vaccination of residents and staff members at enrolled LTCFs. To evaluate early receipt of vaccine during the first month of the program, the number of eligible residents and staff members in enrolled SNFs was estimated using resident census data from the National Healthcare Safety Network (NHSN † ) and staffing data from the Centers for Medicare & Medicaid Services (CMS) Payroll-Based Journal. § Among 11,460 SNFs with at least one vaccination clinic during the first month of the program (December 18, 2020–January 17, 2021), an estimated median of 77.8% of residents (interquartile range [IQR] = 61.3%– 93.1%) and a median of 37.5% (IQR = 23.2%– 56.8%) of staff members per facility received ≥1 dose of COVID-19 vaccine through the Pharmacy Partnership for Long-Term Care Program. The program achieved moderately high coverage among residents; however, continued development and implementation of focused communication and outreach strategies are needed to improve vaccination coverage among staff members in SNFs and other long-term care settings. The Pharmacy Partnership for Long-Term Care Program is a public-private partnership among CDC, CVS Pharmacy (https://www.cvs.com), Managed Health Care Associates, Inc. (https://www.mhainc.com/home), and Walgreens (https://www.walgreens.com) to provide on-site COVID-19 vaccination of residents and staff members at enrolled LTCFs in 54 jurisdictions (49 states, four cities, and one territory). ¶ These organizations report facility-level aggregate vaccine administration data to CDC through a web-based data platform. For this analysis, COVID-19 vaccine administration data were restricted to those from enrolled SNFs with a unique, valid CMS Certification Number (CCN) that had a vaccination clinic conducted on site during the first month of the program (December 18, 2020–January 17, 2021). The number of residents eligible for vaccination was estimated using the mean of NHSN weekly resident census counts for each facility during the weeks of December 14, 2020–January 17, 2021. Resident census data were available for 11,376 facilities; 60 (0.5%) facilities with missing data were excluded from analyses of resident vaccination, as were 24 (0.2%) facilities where the CCN was linked to NHSN reporting from multiple sites. The number of staff members eligible for vaccination was estimated using CMS Payroll-Based Journal counts of unique staff members for each facility during July–September (Quarter 3) 2020. Payroll data were available for 11,134 facilities; 326 (2.8%) facilities with missing data were excluded from analyses of staff member vaccination. To estimate vaccination coverage, vaccine administration data for residents and staff members were matched to denominators for these groups using the facility CCN. National vaccination estimates included all CMS-certified SNFs with available denominator data and at least one on-site clinic in the first month of the program across all participating jurisdictions. Jurisdiction-level estimates are shown only for jurisdictions where >50 CMS-certified SNFs had at least one on-site clinic in the first month of the program and denominator data were available; data for participating cities were combined with those of their respective states for jurisdiction-level estimates. No individual-level data were included in the data files provided to CDC. All analyses were performed using SAS statistical software (version 9.4; SAS Institute). This activity was reviewed by CDC and was conducted consistent with applicable federal law and CDC policy.** During December 18, 2020–January 17, 2021, among 12,702 CMS-certified SNFs enrolled in the Pharmacy Partnership for Long-Term Care Program, 11,460 (90.2%) had at least one on-site vaccination clinic conducted through the program. †† A total of 713,909 residents and 582,104 staff members received ≥1 COVID-19 vaccine doses. §§ Among 11,376 (99.3%) of these facilities with available resident census data, a median estimated 77.8% (IQR = 61.3%–93.1%) of residents were vaccinated; and among 11,134 (97.2%) facilities with available staff member payroll data, a median of 37.5% (IQR = 23.2%–56.8%) of staff members were vaccinated (Figure 1). Among the 54 participating jurisdictions, 40 states had >50 CMS-certified SNFs that conducted at least one on-site clinic during the first month of the program and had available denominator data; the median percentage of residents vaccinated by state ranged from 65.7% to >100% ¶¶ and of staff members, ranged from 19.4% to 67.4% (Figure 2). FIGURE 1 Estimated percentage* of residents † and staff members § at skilled nursing facilities ¶ enrolled in the Pharmacy Partnership for Long-Term Care Program who received ≥1 dose of COVID-19 vaccine — United States, December 18, 2020–January 17, 2021 Abbreviations: CMS = Centers for Medicare & Medicaid Services; COVID-19 = coronavirus disease 2019. * Vaccination coverage >100% (not shown) was estimated for residents in 2,118 (18.5%) facilities and for staff members in 559 (4.8%) facilities. Estimated vaccination coverage in excess of 100% might reflect resident and staff member turnover, other variation in denominator estimates, or errors in reported vaccine administration data. † n = 11,376 facilities. The number of residents eligible for vaccination was estimated using the mean of National Healthcare Safety Network weekly resident census counts for each facility during December 14, 2020–January 17, 2021. § n = 11,134 facilities. The number of staff members eligible for vaccination was estimated using CMS Payroll-Based Journal counts of unique staff members for each facility during July–September (Quarter 3) 2020. Vaccination estimates reflect staff members vaccinated through the Pharmacy Partnership for Long-Term Care Program; additional staff members might have been vaccinated through other programs. ¶ Includes facilities with a unique, valid CMS Certification Number and with at least one on-site clinic conducted through the Pharmacy Partnership for Long-Term Care Program during December 18, 2020–January 17, 2021. The figure consists of two bar charts showing the estimated percentage of residents and staff members at skilled nursing facilities enrolled in the Pharmacy Partnership for Long-Term Care Program who received ≥1 dose of COVID-19 vaccine in the United States during December 18, 2020–January 17, 2021. FIGURE 2 Estimated median percentage of residents* and staff members † at skilled nursing facilities § enrolled in the Pharmacy Partnership for Long-Term Care Program who received ≥1 dose of COVID-19 vaccine, by jurisdiction ¶ — United States, December 18, 2020–January 17, 2021 Abbreviations: CMS = Centers for Medicare & Medicaid Services; COVID-19 = coronavirus disease 2019. * n = 11,376 facilities. The number of residents eligible for vaccination was estimated using the mean of National Healthcare Safety Network weekly resident census counts for each facility during December 14, 2020–January 17, 2021. † n = 11,134 facilities. The number of staff members eligible for vaccination was estimated using CMS Payroll-Based Journal counts of unique staff members for each facility during July–September (Quarter 3) 2020. Vaccination estimates reflect staff members vaccinated through the Pharmacy Partnership for Long-Term Care Program; additional staff members might have been vaccinated through other programs. § Includes facilities with a unique, valid CMS Certification Number and with at least one on-site clinic conducted through the Pharmacy Partnership for Long-Term Care Program during December 18, 2020–January 17, 2021. ¶ Participating jurisdictions do not include West Virginia. Jurisdiction-level estimates are only presented for 40 states that had >50 CMS-certified skilled nursing facilities with a vaccination clinic conducted during December 18, 2020–January 17, 2021. Data for Chicago, New York City, and Philadelphia were combined with those of their respective states for jurisdiction-level estimates. Washington, DC, and Puerto Rico had ≤50 skilled nursing facilities with an on-site clinic and available data and are not shown. The figure consists of two maps of the United States showing the estimated percentage of residents and staff members at skilled nursing facilities enrolled in the Pharmacy Partnership for Long-Term Care Program who received ≥1 dose of COVID-19 vaccine, by jurisdiction, in the United States during December 18, 2020–January 17, 2021. Discussion The Pharmacy Partnership for Long-Term Care Program partners with pharmacy providers to manage the COVID-19 vaccination process, reducing the workload for SNF administrators and jurisdictional health departments by coordinating scheduling, vaccine cold chain management, patient counseling, and vaccine administration. In the first month of the program, more than one million SNF residents and staff members in CMS-certified SNFs received on-site COVID-19 vaccination, with moderately high coverage among residents. Considering the high COVID-19–associated morbidity and mortality in SNFs ( 1 , 2 ) and, particularly, the risk for severe disease among SNF residents ( 3 ), vaccination of this population is a public health priority. However, the lower percentage of staff members vaccinated raises concern about low coverage among a population at high risk for occupational exposure to SARS-CoV-2. Low vaccination coverage among staff members working in LTCFs has been previously described for influenza vaccination; during the 2017–18 influenza season, vaccination coverage among LTCF staff members was lower than that among other health care workers ( 6 ), and survey data suggest that hesitancy among this population could be associated with skepticism about influenza vaccine effectiveness and perceived low risk for virus transmission to themselves or others ( 7 ). Although efforts are ongoing to promote confidence in COVID-19 vaccination among health care workers, challenges persist. According to a survey conducted in October 2020, 37% of nurses stated that they were not confident that a COVID-19 vaccine would be safe and effective, and only 34% agreed that they would voluntarily receive a COVID-19 vaccine.*** Frequently cited reasons for vaccine hesitancy included the perceived rapidity of vaccine development; inadequate information received about vaccine safety, side effects, and administration; and skepticism regarding the clinical trials and vaccine approval processes. Similarly, survey data from December 2020 indicated that nearly one third (29%) of respondents who worked in a health care delivery setting expressed COVID-19 vaccine hesitancy, and updated estimates from January 2021 indicated that hesitancy persisted, with 28% of health care workers indicating a desire to delay receipt of vaccine until they had more information about safety and effectiveness. ††† Specifically among LTCF staff members, a November 2020 survey found that only 45% of respondents were willing to receive a COVID-19 vaccine immediately once available, and an additional 24% would consider it in the future; the most frequently identified reason for vaccine hesitancy was concern about side effects ( 8 ). High staff member turnover, staff members working in multiple facilities ( 9 ), and limited resources for staff member outreach and education ( 10 ) are also potential barriers to vaccination in LTCFs. Use of focused communication messages to increase COVID-19 vaccine confidence in health care personnel §§§ and specifically among LTCF staff members ¶¶¶ , including messages regarding the documented safety and efficacy of authorized COVID-19 vaccines, might help improve vaccination acceptance and coverage. Staff members serve as a trusted source of information for patients and residents; therefore particularly in LTCF settings where residents and staff members might be vaccinated simultaneously, increasing vaccine confidence among staff members might have additional benefits for promoting vaccination among residents. Because coverage varied among jurisdictions, lessons learned from jurisdictions or individual facilities with high coverage might provide insight into strategies that could be applied more broadly. The findings in this report are subject to at least four limitations. First, vaccination procedures for health care workers might have underestimated the percentage of staff members vaccinated. Some jurisdictions encouraged LTCF staff members to be vaccinated through other programs for health care worker vaccination (e.g., clinics conducted by health departments or hospitals); only staff members vaccinated on site through the Pharmacy Partnership for Long-Term Care Program were included in these staff member vaccination estimates. Allocations to pharmacies included adequate vaccine to cover all expected residents and staff members in each facility; however, vaccination of staff members might have been intentionally staggered by SNFs in accordance with CDC’s clinical considerations for health care providers, although staggering is emphasized for second doses in the 2-dose series.**** Similarly, scheduling of clinics could have posed challenges for staff members who worked on a shift schedule or worked at multiple facilities, or staff members might not have been available for vaccination around holidays falling within the time frame evaluated. Systematic data concerning these potential barriers were not recorded, and they require further study. Second, the number of residents and staff members eligible for vaccination at each facility was estimated using secondary data sources and was not determined in real time at each vaccination clinic. The most recent available CMS Payroll-Based Journal data were from July to September 2020 and might have differed from staffing during the time of vaccination clinics. Additional variation in facility occupancy and resident and staff member turnover during December 2020–January 2021 could affect the accuracy and precision of these denominator estimates. Third, these estimates only evaluated the first month of the program; vaccination coverage might have increased as subsequent clinics were conducted at each facility. Vaccination was only evaluated among CMS-certified SNFs because of the ability to match to secondary data sources using the facility CCN; these estimates might not be generalizable to all other LTCFs enrolled in the program (e.g., assisted living facilities and non-CMS certified facilities). Finally, no qualitative data were collected to determine motivators for vaccination or to document and characterize possible vaccine hesitancy suggested by the low percentage of staff members vaccinated. Data on COVID-19 vaccine administration and coverage are essential to evaluating and supporting vaccination efforts over time. Additional data collected for the duration of the Pharmacy Partnership for Long-Term Care Program will characterize the percentage of residents and staff members vaccinated over time, as well as the percentage who complete the 2-dose series. Vaccine administration data can also be used to assess the effects of vaccination on COVID-19 case rates and transmission in high-risk settings; additional data will be collected through the NHSN LTCF Component. †††† Communications resources developed to increase vaccine confidence among LTCF staff members can be employed for public health outreach, and strategies to address structural barriers, such as scheduling around shift work or provision of paid medical leave for possible postvaccination side effects, should be encouraged. Further studies should explore differential vaccination coverage by characteristics, including geographic location, sociodemographic factors, and facility size, as well as characterize barriers to vaccination of persons working in LTCFs; qualitative assessment of attitudes and beliefs might inform additional communication strategies to improve vaccine confidence and increase vaccination among LTCF staff members. Summary What is already known about this topic? Residents and staff members in long-term care facilities, particularly skilled nursing facilities (SNFs), are at increased risk for COVID-19–associated morbidity and mortality and have been prioritized for the first phase of vaccination in the United States. What is added by this report? Among 11,460 SNFs with at least one vaccination clinic conducted during the first month of the CDC Pharmacy Partnership for Long-Term Care Program, a median of 77.8% of residents and 37.5% of staff members received ≥1 vaccine dose through the program. What are the implications for public health practice? Barriers to SNF staff member vaccination need to be overcome with continued development and implementation of focused communication and outreach strategies to improve vaccination coverage.
                Bookmark

                Author and article information

                Journal
                MMWR Morb Mortal Wkly Rep
                MMWR Morb Mortal Wkly Rep
                WR
                Morbidity and Mortality Weekly Report
                Centers for Disease Control and Prevention
                0149-2195
                1545-861X
                03 September 2021
                03 September 2021
                : 70
                : 35
                : 1206-1213
                Affiliations
                Immunization Services Division, National Center for Immunization and Respiratory Diseases, CDC; CDC COVID-19 Response Team; Stat-Epi Associates, Inc., Ponte Vedra Beach, Florida.
                Author notes
                Corresponding author: Bhavini Patel Murthy, bmurthy@ 123456cdc.gov .
                Article
                mm7035e1
                10.15585/mmwr.mm7035e1
                8422871
                34473680
                ce1fad65-3caa-4b9c-a1f7-6c3328cf094d

                All material in the MMWR Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.

                History
                Categories
                Full Report

                Comments

                Comment on this article